The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...

Health secretary Robert F. Kennedy Jr.’s decision to discontinue funding of the development of messenger RNA vaccines is not ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

AstraZeneca is conducting a Phase III clinical study titled A Phase III, Randomised, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With ...

During the first RSV season in which a maternal vaccine and a monoclonal antibody for infants were available, 72% of infants were immunized, this study found. Disparities in access to immunization ...

AstraZeneca (AZN -1.22%) reported an estimates-busting quarter Tuesday morning, and a satisfied market rewarded the company for it. At market close the sturdy pharmaceutical stock had risen by ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 billion investment to expand there, as President Donald Trump pressures ...

AstraZeneca shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates on strong U.S. growth and demand for its cancer drugs.

In V&I Therapies, AstraZeneca recorded $126 million in revenues from Beyfortus, which included alliance revenues mentioned earlier as well as sales of manufactured Beyfortus product to Sanofi.